Antisense Oligonucleotide Therapeutic Approach for Suppression of Ataxin-1 Expression: A Safety Assessment

por O’Callaghan, Brennon, Hofstra, Bente, Handler, Hillary P., Kordasiewicz, Holly B., Cole, Tracy, Duvick, Lisa, Friedrich, Jillian, Rainwater, Orion, Yang, Praseuth, Benneyworth, Michael, Nichols-Meade, Tessa, Heal, Wesley, Ter Haar, Rachel, Henzler, Christine, Orr, Harry T.
Publicado 2020

CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in huntington’s disease

por Yu, Dahyun, Zarate, Nicole, White, Angel, Coates, De’jah, Tsai, Wei, Nanclares, Carmen, Cuccu, Francesco, Yue, Johnny S., Brown, Taylor G., Mansky, Rachel H., Jiang, Kevin, Kim, Hyuck, Nichols-Meade, Tessa, Larson, Sarah N., Gundry, Katherine, Zhang, Ying, Tomas-Zapico, Cristina, Lucas, Jose J., Benneyworth, Michael, Öz, Gülin, Cvetanovic, Marija, Araque, Alfonso, Gomez-Pastor, Rocio
Publicado 2022

Correction to: CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington’s disease

por Yu, Dahyun, Zarate, Nicole, White, Angel, Coates, De’jah, Tsai, Wei, Nanclares, Carmen, Cuccu, Francesco, Yue, Johnny S., Brown, Taylor G., Mansky, Rachel H., Jiang, Kevin, Kim, Hyuck, Nichols‑Meade, Tessa, Larson, Sarah N., Gundry, Katherine, Zhang, Ying, Tomas‑Zapico, Cristina, Lucas, Jose J., Benneyworth, Michael, Öz, Gülin, Cvetanovic, Marija, Araque, Alfonso, Gomez‑Pastor, Rocio
Publicado 2022